CNS Pharmaceuticals files Form 3 for its CFO

CNS Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Steve O'Loughlin.

Accepted by SEC EDGAR 03/04/2026 - 05:00 PM EST

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CNS Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Steve O'Loughlin. This Form 3 confirms his status as an officer who is subject to insider reporting rules, but does not list any specific stock transactions or changes in ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the CNSP Form 3 filing for Steve O'Loughlin show?

The Form 3 for CNS Pharmaceuticals’ CFO Steve O'Loughlin reports his status as an executive insider. It establishes his reporting obligations for future trades in CNSP securities under SEC rules governing insider ownership and transactions.

Did CNS Pharmaceuticals CFO Steve O'Loughlin buy or sell CNSP shares in this Form 3?

This Form 3 does not report any stock purchases or sales by CNS Pharmaceuticals’ CFO. It serves as an initial ownership statement, setting up ongoing disclosure of any future insider transactions in CNSP shares.

Why did CNS Pharmaceuticals file a Form 3 for its CFO?

CNS Pharmaceuticals filed a Form 3 because Steve O'Loughlin is its Chief Financial Officer. Executives must file this initial ownership report when they become insiders, before reporting any later trades on Forms 4 or 5.

Does the CNSP Form 3 indicate major insider activity?

The CNSP Form 3 for Steve O'Loughlin does not indicate major insider activity. It contains no reported transactions and primarily establishes his insider status for future ownership and trading disclosures.

How does this Form 3 affect CNSP shareholders?

This Form 3 mainly provides regulatory transparency for CNSP shareholders. It confirms that the Chief Financial Officer is now formally subject to insider reporting, which helps investors track any future executive trades in the company’s stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

O'Loughlin Steve

(Last)

(First)

(Middle)

C/O CNS PHARMACEUTICALS, INC.

100 WEST LOOP SOUTH, SUITE 900

(Street)

HOUSTON

77027

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/02/2026

3. Issuer Name and Ticker or Trading Symbol
CNS Pharmaceuticals, Inc. [ CNSP ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Christopher Downs, Attorney-in-fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR